WT1 is a developmentally regulated kidney zinc finger transcription factor which is inactivated in the germline of children predisposed to Wilm's tumor. Both loss of WT1 and overexpression of WT1 lead to apoptosis of renal stem cells critical to kidney development and function. Although WT1 is known to bind to a GC-rich consensus sequence and to repress the activity of promoters with which it interacts, there remain a paucity of genes identified as physiological WT1 targets. WT1 is alternately spliced but no specific function has been assigned to the different splice forms that are prevalent. Thus, while WT1 is a paradigm for a tissue-specific tumor suppressor, little is known about its function, regulatory pathways, and role in tissue differentiation. Dr. Haber proposes to analyze a candidate target gene he has identified, the cell cycle kinase inhibitor p21, and to identify other potential target genes using an inducible cell system. He also aims to identify WT1-binding proteins by two hybrid and immunological approaches. Two model systems are proposed for use to study the functional interactions with candidate target genes and binding proteins. The first system is based on a kidney stem cell assay and the second on a hematopoietic model in which WT1 appears to contribute to development arrest and leukemogenesis. Finally, Dr. Haber proposes to seek other potential Wilm's tumor genes using his collection of normal/tumor pairs of DNAs and the RDA approach developed by Lisitsyn and Wigler.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA058596-08
Application #
6137510
Study Section
Pathology B Study Section (PTHB)
Program Officer
Gallahan, Daniel L
Project Start
1993-01-01
Project End
2002-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
8
Fiscal Year
2000
Total Cost
$314,231
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Zhang, Hong; Christoforou, Andrea; Aravind, L et al. (2004) The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein. Mol Cell 14:841-7
Smolen, Gromoslaw A; Vassileva, Maria T; Wells, Julie et al. (2004) SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res 64:7846-51
Zhang, Hong; Azevedo, Ricardo B R; Lints, Robyn et al. (2003) Global regulation of Hox gene expression in C. elegans by a SAM domain protein. Dev Cell 4:903-15
Zhang, Hong; Palmer, Rachel; Gao, Xiaobo et al. (2003) Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. Curr Biol 13:1625-9
Yajnik, Vijay; Paulding, Charles; Sordella, Raffaella et al. (2003) DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell 112:673-84
Wong, Jenise C; Lee, Sean B; Bell, Moshe D et al. (2002) Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene 21:2009-19
Palmer, R E; Kotsianti, A; Cadman, B et al. (2001) WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol 11:1805-9
Ellisen, L W; Palmer, R E; Maki, R G et al. (2001) Cascades of transcriptional induction during human lymphocyte activation. Eur J Cell Biol 80:321-8
Ellisen, L W; Carlesso, N; Cheng, T et al. (2001) The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 20:1897-909
Lee, S B; Huang, K; Palmer, R et al. (1999) The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98:663-73

Showing the most recent 10 out of 26 publications